Skip to main content

Advertisement

In silico approach in reveal traditional medicine plants pharmacological material basis

Article metrics

Abstract

In recent years, studies of traditional medicinal plants have gradually increased worldwide because the natural sources and variety of such plants allow them to complement modern pharmacological approaches. As computer technology has developed, in silico approaches such as virtual screening and network analysis have been widely utilized in efforts to elucidate the pharmacological basis of the functions of traditional medicinal plants. In the process of new drug discovery, the application of virtual screening and network pharmacology can enrich active compounds among the candidates and adequately indicate the mechanism of action of medicinal plants, reducing the cost and increasing the efficiency of the whole procedure. In this review, we first provide a detailed research routine for examining traditional medicinal plants by in silico techniques and elaborate on their theoretical principles. We also survey common databases, software programs and website tools that can be used for virtual screening and pharmacological network construction. Furthermore, we conclude with a simple example that illustrates the whole methodology, and we present perspectives on the development and application of this in silico methodology to reveal the pharmacological basis of the effects of traditional medicinal plants.

Background

Over three quarters of the world’s population relies mainly on plants and plant extracts for health care. World Health Organization (WHO) report indicated that over 30% of all plant species have at one time or another been used for medicinal purposes [1]. The scientific study of traditional medicinal plants is of great importance for human health.

Identifying and predicting the pharmacological basis of the activity of traditional medicinal plants are important for the goal of modernizing their use [2]. Because the chemical constituents of medicinal plants are complex and varied, clarifying the specific chemical components in such plants and their major biological functions is a complex task.

The traditional model of medicinal plant research can usually be divided into the following steps: first, the extraction of compound monomers or fractions, followed by their qualitative and quantitative identification and then a variety of pharmacological experiments such as in vitro experiments and injection or feeding these solution in animal then performing effective measurement [3]. In general, the whole research process is time consuming and expensive. However, several parts of this common approach can be modified to improve the efficiency. At present, the chemistry of the most widely used medicinal plants, such as ginseng and licorice, has been studied quite thoroughly. Hundreds of chemical compounds have been extracted from these medicinal herbs. However, most of these compounds have not to be studied whether they have potential no biological activity. It would be a vast and time-consuming project to systematically evaluate the activities of these ingredients by conventional methods.

In recent years, with an increasingly in-depth understanding of the structure and function of compounds, a series of new technologies and methods have been applied to the development of medicinal plants [4]. If we can establish a quick and convenient pathway by which to first accurately predict a large number of chemical compounds and then, based on these results, perform in vivo and in vitro pharmacological experiments for verification, this procedure will significantly improve the efficiency of evaluating the chemical activities of medicinal plants [5]. Back to 1950s, Artemisinin, the most famous antimalarial drug, was also obtained through large-scale screening from herbs. After that, several FDA approved drugs were developed from natural herbs or animal through the in silico approaches. The first case use enzyme-inhibitor structure to develop drug was the Angiotensin converting enzyme inhibitor-Captopril in 1970s [6]. And the first FDA approved HIV-1 enzyme inhibitor—Saquinavir also developed by in silico approaches [7]. Nowadays, with the continuous advancement of computer science, successful examples of finding drugs from natural products using computer-aided drug design methods have become more frequently, such as Dozamide (Approved by FDA in 1995), Imatinib (Approved by FDA in 2001), Dasatinib (Approved by FDA in 2006), and Ponatinib (Approved by FDA in 2012) [8]. With the continuous maturation of computer technology, the in silico approach of utilizing a computer platform to calculate the combinations of simulated compounds and targets has become increasingly accurate. In addition, the development of network pharmacology technologies has enabled the rapid elucidation of the complex relationships between compounds and their various activity targets [9]. Traditional Chinese medicine (TCM) involves a highly complex system of chemical substances. Its complexity is not only reflected in the composition of the chemical constituents but also embodied in the network of relationships between the prescription and the human body and the exertion of pharmacological effects through multiple channels, multiple targets and the overall regulatory mechanism [10].

Regarding the implications of Chinese medicine informatics, the application of modern informational technology to study TCM must address information on a variety of characteristics of the medicines themselves, as well as the interactions between TCMs and the human body [11]. The definition of Chinese medicine informatics is as follows: an interdisciplinary science that applies information science theory and computer technology to study the regulation and process of TCM information flow and investigates the views of TCM practitioners for the purpose. The definition of network pharmacology is as follows: a new discipline based on systems biology theory, in which the network analysis of biological systems is used to select the characteristics of signal nodes for multi-target small molecular drug design [12]. Therefore, we can treat a single medicinal plant with the same complexity as TCM, utilizing technical means from TCM informatics and network pharmacology to explore the chemical composition and the potential pharmacological foundation of the plant’s effects. In this paper, we elucidate the methodology in detail (Fig. 1).

Fig. 1
figure1

The overall design of the methodology

Design of the methodology

In this paper, we elucidate the methodology in detail (Fig. 1). Considering the medicinal plant as the object and virtual computational screening as the central methodology within Chinese medicine informatics, and using network pharmacology as the technical means, we have employed a set of effective and accurate methods to reveal the pharmacological basis of the effects of medicinal plant materials and predict the potential bioactivity of their compounds. The approach proceeds from the selection of the plant compounds to virtual screening and evaluation of the targets, related signalling pathways and disease networks. Techniques from virtual computational screening, Chinese medicine informatics and network pharmacology are used to construct a complete technical routine for this methodology. The first step is to confirm the research significance of the plants. These medicinal plants can be organized into three categories: (1) common herbs with a more complex mechanism than that of other herbs; (2) herbs with a long history of traditional usage but fewer studies on their phytochemistry and pharmacology; and (3) herbs with a history of traditional usage but now with a new utilization. The second step is the organization and collection of the natural products to construct the natural products database. The third step is the pre-treatment of these compounds, including drug-like analysis, ADME/T (absorption, distribution, metabolism, excretion and toxicity) prediction and the exclusion of false-positive compounds. The fourth step is the core technique of this methodology, the in silico virtual screening. We designed this step by combining three different theoretical bases: the first is virtual target fishing based on pharmacophore theory; the second is dual validation based on small molecule shape similarity theory; and the third is compound-target analysis based on docking. The fifth step is the analysis of the set of targets identified. By utilizing the technical methods of network pharmacology and different protein information databases and websites, we can analyse the relationships of signalling pathways, pathological pathways and related diseases with potential targets. Finally, we construct the network of relationships among medicinal plants, natural compounds, biological targets, signalling pathways, and diseases. We thereby elucidate the mechanistic basis of the effects of the natural compounds in medicinal plants and predict their potential pharmacological activities.

Confirmation of the objective

At present, the pharmacological mechanisms of numerous single compounds extracted from herbs have been elucidated. However, herbs contain diverse and complex compounds that are involved in multiple biological pathways and that correspond to different diseases. Therefore, investigating the different types of medicinal plants and their chemical constituents is a task with both broad and specific significance. We have recommended three categories of herbs that are suitable for the use of the in silico approach to unveil their chemical mechanisms. The first type of medicinal plants can be described by “common usage, but their mechanism is more complicated”, such as Panax notoginseng (Burk.) F. H. Chen (Notoginseng), which is mainly cultivated in Yunan, China [13]. The medicinal part of notoginseng is its dry roots, and their main clinical activity is “scattered blood stasis, swelling pain”. The noteworthy point is that notoginseng can not only promote blood circulation but also stop bleeding. The common theory regarding this two-way regulatory function is that the notoginseng saponins can invigorate the circulation of blood, while dencichine performs a haemostatic function [14]. Therefore, it is necessary to identify the pharmacological basis of the effects of the constituents of these herbs. The second type of medicinal plants is ones that “have a long history of traditional usage, but their study is in the early stages and not yet mature”. Several medicinal plants in different regions have a history of more than 1000 years of traditional usage, such as “Peruvian ginseng” Lepidium meyenii Walp (maca), which is mainly distributed in the Andean mountains in the south of Peru at an altitude greater than 3000 m. The local people have consumed the subterranean part of maca to enhance their energy, improve their fertility and sexual function, or treat menopausal syndromes, rheumatism, depression, and anaemia for more than 1000 year [15]. However, pharmacological research on such plants only began in the last decade, so research on these medicinal plants is particularly important and urgent. The third category of medicinal plants are those that have new and different uses. To shorten the development cycle of new drugs, reduce risk and improve the success rate, new uses of traditional herbs in other diseases are often proposed. Berberine, also known as puerarin, is mainly extracted from Coptis chinensis Franch and has anti-bacterial activity. In vitro experiments show broad-spectrum anti-bacterial activity, which is mainly used clinically to treat digestive system infections such as acute gastroenteritis and dysentery. Interestingly, in recent years, researchers have found that berberine has an excellent effect in the treatment of cardiovascular disease [16]. Artemisinin, extracted from Artemisia annua L., was the most efficient anti-malarial drug in use for decades. Researchers have recently found that it can also counteract tuberculosis, diabetes, and trauma, treat systemic lupus erythaematosus and perform other pharmacological functions [17].

Research on the development and utilization of three types of medicinal plants is particularly likely to be valuable. Once the objectives (medicinal plants) have been selected for study, we can perform the next step, the collection of their compounds.

The acquisition of chemical compound information

A thorough understanding of the effective compounds in medicinal plants is the key to the research and development of medicinal plants. Therefore, the collection of constituent information and the construction of the compound database are highly important for their application. The construction of a compound database can effectively manage the large quantities of compounds found in medicinal plants.

Collection of chemical compound information

The information contained in a medicinal plant is the initial raw material for determining the basis of the herb’s pharmacological properties. Compound information was mainly collected from the following sources: (1) separation and purification of the compounds in a local laboratory; (2) literature reports; and (3) small molecule compound databases. Among these three information-gathering pathways, the extraction of compounds in a local laboratory is the most direct and convenient method and can provide samples for later experimental studies. When a single compound is purified from herbs, the relevant information such as its recording number, CAS number, name, source plant, extractive fraction and structure information such as the SMILES code or InChiKey must be recorded. The compounds obtained from the laboratory are doubtless the best research objects; however, these compounds are often either relatively simple or difficult to obtain intact as constituents of a given herb. Therefore, the literature and various databases may offer a simple way to collect information on a set of different compounds from our herb of interest. To use these resources, relevant information such as the name, structure, classification and plant source must be recorded. With the continuous upgrades to virtual screening technology, the online large-scale direct search database has become a quicker and more convenient approach. At present, various research institutions, laboratories, government agencies and pharmaceutical enterprises have developed and constructed a number of small molecule compound databases reporting different characteristics and functions (Table 1).

Table 1 Common small molecular databases overview

Software and database of medicinal plant compounds

Many commercial or access-restricted software programs or websites can satisfy the needs of constructing a medicinal plant compound database. Different software programs focus on specific functions embodied in diverse storage formats, for instance, the accdb format of Microsoft Company, the MDB format within the MOE software, and the SDF format from Accelary Discovery Studio. A complete medicinal plant compound database must provide at least the following descriptors: (1) compound storage number; (2) compound name and CAS (Pubchem) ID; (3) sources of plant information (Latin name and extractive fraction); and (4) compound structure (SMILES code, InChiKey). In addition, several software programs can also calculate the relative molecular weight, the lipid partition coefficient (AlogP), the number of rotatable bonds, the number of hydrogen donors/receptors and other physical and chemical properties of compounds. The combination of all this relatively trivial information can make follow-up work requiring transparency and data processing more convenient.

Pre-treatment of chemical compounds

The number of compounds collected from medicinal plants is very high; however, the majority lack pharmacological potency. To enhance the efficiency of screening, the first step is to remove these non-potential compounds and refine the included compounds.

Prediction of drug-like properties

Drug-like characteristics are a qualitative concept used in drug design for a compound’s utility with respect to factors such as bioavailability, which is estimated based on the molecular structure characteristics [31]. Certain structure properties indicate that a compound has a higher likelihood of becoming a successful drug. In the past, research on these properties of a drug has been among the most important components of downstream drug development. In recent years, it has become imperative to integrate the study of drug properties during the early stages of drug discovery. Pharmacologists are interested in the following properties of the drugs, among others: (1) structural characteristics: hydrogen bonding, polar surface area, lipophilicity, shape, molecular weight, and acid dissociation constant (pKa); (2) physicochemical properties: solubility, pH value, permeability and chemical stability; (3) biochemical properties: metabolism, protein binding affinity and transport ability; and (4) pharmacokinetics and toxicity: half-life, bioavailability, drug interactions and half lethal dose, LD50. According to Lipinski’s proposal [32], a small molecule suitable for development as a drug needs the following properties (Lipinski’s rule of five, RO5): (1) no more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds); (2) no more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms); (3) a molecular mass less than 500 Daltons; and (4) an octanol–water partition coefficient logP not greater than (5) Small molecules that satisfy the RO5 criteria have higher bioavailability in the metabolic process of the organism and therefore are more likely to become oral medications. In 2002, Veber and his group presented another set of system requirements for the oral administration of drugs that included the molecular flexibility, polar surface area (PSA) and number of hydrogen bonds, which were determined by a series of studies in rats: (1) no more than 10 rotatable bonds and (2) polar surface area no more than 140 Å2 or no more than 12 hydrogen bonds and receptors [33]. However, there are still exceptions for special drug screening such as narcotic drug screening, which cannot rule out small molecular weight compounds, and those anti-tumour drugs cannot exclude metal organic compounds. Nowadays, several softwares can performing the drug-likeness prediction. Such as the Instant JChem from ChemAxon company which can calculate the RO5 properties, and the Discovery Studio software can both predict the Lipinski and Veber’s rules [34].

ADME/T selection

When drug-likeness established from the analyses of the physiochemical properties and structural features of existing drug candidates, the ADME/T (absorption, distribution, metabolism, excretion and toxicity) properties play an important role in the drug filtering. So, we employed the ADME/T selection after other drug-likeness properties evaluated.

It is necessary to predict the situation and movement of a drug in the human body during the design of the drug molecule. During the early stages of drug design, the ADME/T properties of a drug are evaluated [35]. Absorption is the process of drug transport into the human circulatory system. Distribution is the penetration of the drug through the cell membrane barrier into the various tissues, organs or body fluids. As metabolism occurs, the initial (parent) compound is converted to new compounds called metabolites. The majority of small-molecule drug metabolism is carried out in the liver by redox enzymes, termed cytochrome P450 enzymes. Excretion is the removal of the initial form and metabolites of the drug from the human body. The toxicity of the drug also affects the human body. Several commercial software programs have equipped the ADME/T prediction module for drug molecules. For instance, the commercial software Discovery Studio provides an ADME/T descriptor module for candidate drug screening, which contains the following aspects: aqueous solubility, to predict the solubility of each compound in aqueous solvent; blood brain barrier penetration, to predict the ability of compounds to penetrate into the brain; and CYP2D6 enzyme binding capacity. The CYP2D6 enzyme is an important member of the CYP450 enzyme family and participates with the CYP3A4, CYP1A2, CYP2C9, and CYP2C19 enzymes in drug metabolism. The five major CYP enzymes are responsible for more than 95% of the drug metabolism in animals. The CYP2D6 enzyme normally accounts for approximately 2% of the CYP total but approximately 30% of the total drug metabolism. In clinical practice, the high CYP2D6 enzyme binding capacity of drug can reflect its excellent metabolism ability in the human body. The relevant criteria involve hepatotoxicity, the dose-dependent liver toxicity of the drug molecules; intestinal absorption, the absorption of drug molecules in the human body after oral administration; and plasma protein binding, the ability of the compound to bind to the carrier protein in the bloodstream.

Suitable pharmacokinetic properties and low toxicity during body absorption, distribution, metabolism and excretion are the key factors in successfully passing the clinical trials. Predicting the ADME/T properties of drug molecules prior to drug design and performing this screening can reduce the cost of drug development and improve the success rate of the whole procedure. For ADME/T properties rational predictive have been developed on mechanistic descriptions of the underlying biophysical processes. Some softwares can performing ADME/T such as Simulations Plus ADME/T predictor [36], PK-Map the Discovery Studio from Accerlary company [37].

Exclusion of false-positive compounds

Due to accidents or other reasons, some false-positive compounds are also included in the filtered sample library for the post-screening step. Most of these false-positive compounds are easily decomposed under hydrolytic conditions and react with proteins or biological nucleophiles (glutathione, dithiothreitol, etc.), which are easily detected by a positive result in an enzyme system or cell test. In fact, these false-positive compounds are mostly chemical reaction intermediates such as epoxides, aldehydes, haloalkanes, or compounds consisting of a conjugated system.

The concept and performance of virtual screening

The virtual screening of drugs can be defined as follows: based on the theories of drug design and new drug screening, with the aid of computer technology and professional software, selecting the theoretically active lead compounds from large quantities of compounds and then evaluating the activity experimentally. Virtual screening methods have three main theoretical foundations: molecular docking, pharmacophore theory, and small molecular shape similarity. According to the author’s work experiences: these three methods have different applications and their own advantages and disadvantages (Table 2, Fig. 2).

Table 2 Three virtual screening methods comparison
Fig. 2
figure2

Demonstration of virtual screening methods

Molecular docking relies on the characteristics of the receptor (drug target/protein/enzyme) itself and the interaction pattern with its small molecule ligand to perform drug design based on the ligand-receptor binding mode (the lock and key principle) [41]. The electrostatic interactions, hydrogen bonding, hydrophobic interaction and van der Waals forces are calculated to predict the ligand’s binding mode and affinity. The pharmacophore is an abstract set of molecular features that are necessary for the molecular recognition of a ligand by a biological macromolecule [42]. The pharmacophore group refers to the spatial arrangement of the pharmacological characteristics of the small molecule in the drug, including the hydrogen bond donors, hydrogen bond acceptors, positive and negative charge centres, aromatic ring centre, hydrophobic groups, hydrophilic groups and geometric conformation. The biological activity of small molecules can be predicted by the summary of their pharmacological feature elements. Small molecule shape similarity can be defined as a database search technique based on the quantitative structure–activity relationships of compounds with the same mechanisms [43]. These three types of common screening software and their characteristics are listed in Table 3.

Table 3 Common virtual screening softwares overview

The focus of our research is to find the pharmacological basis of the effects of the constituents of medicinal plants. From this perspective, the pharmacophore model can be used to screen the large quantities of compounds from medicinal plants. In contrast, from the perspective of diseases and proteins, it is possible to use molecular docking to find the most likely active constituents.

Therefore, we design this core section methodology as follows: first, we perform batch screening based on the pharmacophore model theory to obtain the potential set of binding drugs. Subsequently, these results are verified by use of the small molecule shape similarity theory. Finally, when the target protein requires detailed study, molecular docking can be used to refine the active small molecules.

Virtual screening based on pharmacophore model

The geometrical matching and energy matching process between a drug molecule and its receptor are necessary features for the binding interaction. Different group structures exert different effects on the activity, while similar chemical characteristics have the same or similar pharmacological activities. The concept of the pharmacophore was first described by Paul Ehrlich in 1909 [63]. The pharmacophore refers to the molecular framework of atoms with active and essential features that allow identification of their pharmacological activities. In 1977, Peter Gund further defined the pharmacophore as a group of molecular features that participate in a molecular biological activity. At present, the definition of the pharmacophore is pharmacodynamics elements and their spatial arrangement. These ‘potency elements’ can be specific atoms such as an oxygen atom or carbonyl group or abstract functional structures: hydrogen bond acceptor/donor, positive/negative ionizable charge, aromatic ring, hydrophilic group, the location and orientation of atoms, or the distance, tolerance and exclusion volume of atoms. The pharmacophore is a summary of a series of biologically active molecules that effectively describes the structural features that play the most important roles in activity. The pharmacophore is not representative of a single molecule or a specific functional group. It can represent a group of compounds and the important interaction information on the same receptor class or can be considered a large number of active compounds with common drug characteristics. The construction of a pharmacophore model can be used for the virtual screening of a small molecule library, searching for new skeletal active molecules, predicting the activity of compounds, and optimizing and modifying them. The pharmacophore can also qualitatively quantify the structure–activity relationships of compounds and elucidate the selectivity mechanism of the compounds [64]. During the process of virtual screening, the pharmacophore model can be used to characterize the active conformation of the ligand molecule by conformational search and molecular superposition, and the possible mode of action between the receptor and the ligand molecule can be deduced and explained accordingly.

In addition, a reverse search based on the pharmacophore can solve several common issues focused on the chemical constituents of the medicinal plants, such as its specific targets, therapeutic effect and how to find or construct a similar role among synthesized compounds. Currently, the active ingredients of the medicinal plans can be elucidated by utilizing different commercial software launched by many companies, which can afford virtual screening modules based on pharmacophore theory. We recommend The Discovery Studio developed by the Accelary Company, which equipped the PharmaDB and Hypo DB, these databases contained thousands of pharmacophore models from sc-PDB recorded information.

Validation based on ligand molecule shape similarity

Molecular shape similarity analysis is based on the similarity of small molecules as the index for the database mapping search. Similar to pharmacophore theory, molecular shape similarity analysis can effectively utilize the overall structural characteristics of those compounds. For now, molecular shape similarity analysis is specifically applied to scaffold hopping and shape discrimination [65].

Due to the rule that “molecules with similar structure may have similar or the same biological activity”, during the drug design process, a pharmacist might choose the ligand shape similarity screening method. Generally, small molecule compounds with known activity and targets are used to search for the molecular structure of chemicals in the compound database according to the shape similarity of the potential sample compounds.

During the establishment of this methodology, since the molecular shape similarity screening approach involves a faster process but more challenging result limitations and peculiarities, this method is not suitable for use as the main approach in virtual screening but rather as a validation based on efficacy. At present, many commercial software programs can perform molecular shape similarity operations, including CerberuS, FlexS, and MIMIC. We suggest to choose the WEGA (weighted Gaussian algorithm), is a typical virtual screening method based on ligand shape similarity that was established by Professor Xu Jun’s group from Sun Yat-sen University [56]. The WEGA already can performing in TianHe No. 2 supercomputing platform to ensure its efficiency. The accuracy of the results from another pathway can be evaluated by comparing the shape similarity between the small molecules of those ligands corresponding to the known drug targets and the small molecules yet to be tested.

Accurate verification based on molecular docking theory

The conceptual basis of molecular docking originated from the “lock and key principle model” proposed 100 years ago. The principle of molecular docking is to place a series of test compounds with known three-dimensional structures in turn at the active site of the biological target molecule [66]. The optimal binding conformation of the compound with the target molecule is found by continuously improving the conformation, position, dihedral angle of each rotatable bond, and amino acid residue side chain and backbone of the compound in space and predicting their combination patterns and affinities. The molecular docking method can use a variety of scoring standards to select the most natural conformation of the compound and optimize its affinity to the target according to theoretical analogue molecular interactions. Autodock, FlexX, ICM, GoldDocK, Ligand-Fit and Glide can all perform molecular docking. Due to the accuracy, sensitivity and specificity of the molecular docking, we can use it to refine the results obtained from the pharmacophore model and shape similarity theory. The Autodock is the most used tool for molecular docking in recently years due to its fast and friendly interface. We also recommend LigandFit algorithm: A method employs a cavity detection algorithm for detecting invaginations in the protein as candidate active site regions. A shape comparison filter is combined with a Monte Carlo conformational search for generating ligand poses consistent with the active site shape. Candidate poses are minimized in the context of the active site using a grid-based method for evaluating protein–ligand interaction energies and due to its can comparing enormous poses of ligands, which is suitable for high-throughput screening.

Analysis of target sets

Analysis and annotation of target information

After obtaining the druggable targets by virtual screening, we need to analyse the relevant information on the targets: target type, protein structure, binding pocket shape, associated pathway and corresponding diseases. The targets are usually nominated according to their UniProt ID. UniProt is an abbreviation for the Universal Protein Database program, which consists of the Swiss-Prot, TrEMBL and PIR-PSD databases and is the largest database containing the most informative data resources and protein structures [67]. Using the UniProt ID, detailed information regarding the target protein can obtained at the UniProt website (http://www.uniprot.org/), including the protein name, gene name, organism, sequence information, taxonomy, family and domains, and related molecular functions and biological processes. This database can also link to other databases by searching based on the PDB ID, KEGG ID and other information. In addition to UniProt, many other databases and software programs can also analyse the category and function of these fished targets and their corresponding diseases. Table 4 summarizes the commonly used databases and analysis software.

Table 4 Common druggable targets/protein databases overview

Construction of network pharmacology

In contrast to the chemical drug action model, traditional medicinal herbs, TCMs or formulas all have a wide variety of ingredients, a broad range of drug targets and complex mechanistic characteristics, leading to challenges in elucidating their mechanisms and action models. Network pharmacology is based on the theory of systems biology. It treats each drug, target, gene, pathway and disease as a specific signal node and each action model as an edge to construct a topological network map of their complex relationships [85]. The multi-component, multi-target and multi-pathway mechanisms of medicinal plants can be elucidated by analysing the interrelationships in this topological network map, making traditional medicinal plants available for modern research and innovation. A variety of software programs and web databases can currently analyse the relevant information on target sets and their related pathways and diseases. Examples include the Ingenuity Pathway Analysis (IPA) software from QIAGEN Bioinformatics [86], the KEGG pathway database developed by Kyoto University [87] and MetaCore by Thomson Reuters [88]. The analyses of the principles and characteristics performed by each program also vary. The Causal Network Analysis and Upstream Regulator Analysis tools in IPA can predict the type of disease and associated signalling pathways that correspond to a list of genes and give separate weights for the resulting compound data set. MetaCore uses a massive collection of literature information to identify the small molecules and related proteins corresponding to the underlying disease pathways.

Through the above steps, we can obtain a large amount of information on a medicinal plant, compound, target, pathway, or disease and its interrelationships by analysing the results of the virtual screening and target analysis. Different network visualization tools can show the relationships between these related nodes. Commonly applied software programs and their features are summarized in Table 5. Among them, the open access software Cytoscape is currently the most widely used tool due to its powerful graphical effects and its extensive compatibility with other software programs and databases. The core function of Cytoscape is network construction, which can build a two-dimensional topological network map within each node by edges and then concisely and clearly analyse the pharmacological basis and mechanism of medicinal plants. Each type of node (protein, compound and disease) and their relationship strength can be edited and analysed separately. Cytoscape can also link directly to external public databases and currently offers a variety of plugins to satisfy diverse analysis requirements. Pajek means spider in Slovenian and is another software program for network analysis. Pajek has the ability to break a large and complex network into smaller networks to utilize more efficient methods for further processing. It can also supply powerful visualization tools to implement large-scale (subquadratic) network algorithm analysis.

Table 5 Common visualization tool overview

Vine tea (VT) originates from the plant Ampelopsis grossedentata, which belongs to the family Vitaceae. VT is mainly distributed in the south of China, and pharmacological studies have shown that it has anti-inflammatory and anti-tumour functions and can decrease hypoglycaemia and protect liver function [96]. However, its specific activity components and their mechanism remain unclear. Using the methodology constructed previously, its mechanism can be adequately predicted.

Firstly, we collected 94 compounds from VT which were all reported, and all chemical structures were prepared in SD format. Molecular energy was minimized using the Energy Minimization module of Discovery Studio version 4.5 (DS 4.5; Accelrys Inc., San Diego, CA, USA) under the chemistry at Harvard Macromolecular Mechanics (CHARMM) force field and construction of the 3D multi-conformational VT compounds molecular structure database (VT-DB), which was generated by a Monte Carlo-based conformational analysis (FAST mode). After ADME/T selection in DS4.5 ADME/T property module, the pharmacophore-based target fishing was performed in DS4.5. All those fished protein targets were through the second refine by using WEGA validation. For each target, the protein name, gene name, and pathway information were collected from the PDB, KEGG, DRUNGBANK and TDD. The overall VT compound-target-pathway networks were generated using Cytoscape V3.2.

In Fig. 3, the topological analysis of the interaction network provides insights into its biologically relevant connectivity patterns. The pharmacological network of VT contains three types of nodes. The compounds extracted from VT form the external part of the network (pink octagon) and surround their fished target nodes (blue quadrangle). Each target is linked to at least one disease (green circle). A general overview of the global topological properties of the VT network can obtained from this figure. The figure clearly shows that the effects of the compounds in VT are usually “multiple to multiple”, which reflects the material basis of the VT and its hypoglycaemic and lipid-lowering activities.

Fig. 3
figure3

The topological network relationships between compounds, targets and diseases associated with VT

Conclusion and perspectives

In this paper, we have proposed a wide-ranging complete technical route that utilizes a series of in silico approaches to reveal the pharmacological basis of the effects of medicinal plants, first to determine the object of study and then to obtain its natural constituents and construct the compound database. After pre-processing of the included compounds, a three-step virtual screening is performed. Finally, network pharmacology tools can be used to analyse the target set obtained from the screening; sketch out the network topological map of the medicinal plants, natural constituents, biological targets, associated pathways, related diseases and their interactions; and elaborate on the results.

The proposed joint methodology combines multiple in silico approaches and, through the full use of a series of virtual screening and network pharmacology tools, can clarify the substance basis and the mechanism of medicinal plants. The first half of this methodology uses software technology, including compound activity forecasting and virtual screening, all based on mass experimental data, to provide pinpoint accuracy. This methodology is superior to conventional screening because it requires only structural information on compounds and can perform multi-target screening of a vast number of compounds in a relatively short period of time, which can drastically reduce the cost and time of drug development. Moreover, combining this in silico methodology with pertinent pharmacological experiments could significantly enhance the efficiency of medicinal plant research and new drug discovery. The latter half of the methodology is guided by network pharmacology theory and uses multiple analysis tools and related databases to obtain relevant information from massive bio-information resources; build a network topological map of medicinal plants, chemical constituents, genes, proteins, pathways and diseases; and perform data mining and analysis.

This in silico methodology can resolve the status of medicinal plants that are difficult to study on a practical level and can predict and clarify the mechanisms of the active ingredients in medicinal plants.

Although computer-aided drug design and network pharmacology have been widely used and developed, there still have deficiencies and limitations: (1) The model maturity and computational accuracy of computer docking algorithms need to be further improved. (2) Due to the structure-based methodology, several compounds are not suitable for computer-aided design because of their special structure characteristics. (3) A large number of databases can improve different information for the obtained potential targets, the progress of the selection of these databases and their effective information annotation, still requires continuously practical activities to optimize. With the advancement of computer science, and the constant optimization of algorithms, including the maturity of the protein model. Through more practical researches and development examples to upgrade the entire process of in silico methodology, we believe that in the future, this methodological process will enable the discovery of new drugs more efficiently, accurately and quickly. This methodology will be more widely usable in future work on revealing and predicting the basis of medicinal materials.

Abbreviations

TCM:

Traditional Chinese medicine

ADME/T:

absorption, distribution, metabolism, excretion and toxicity

RO5:

Lipinski’s rule of five

WEGA:

weighted Gaussian algorithm

VT:

vine tea

References

  1. 1.

    Schippmann U, Cunningham AB, Leaman DJ. Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. Rome: FAO; 2002. p. 142–67.

  2. 2.

    Koutsoukas A, et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteom. 2011;74(12):2554–74.

  3. 3.

    Zhang X, et al. Danshen-Chuanxiong-Honghua Ameliorates cerebral impairment and improves spatial cognitive deficits after transient focal ischemia and identification of active compounds. Front Pharmacol. 2017;8:452.

  4. 4.

    Yi F, et al. In silico approach for anti-thrombosis drug discovery: P2Y1R structure-based TCMs screening. Front Pharmacol. 2016;7:531.

  5. 5.

    Yi F, et al. In silico profiling for secondary metabolites from Lepidium meyenii (maca) by the pharmacophore and ligand-shape-based joint approach. Chin Med. 2016;11(1):42.

  6. 6.

    Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011;17(10):1217–20.

  7. 7.

    Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1(8):621–36.

  8. 8.

    Ghosh AK, Gemma S. Structure-based design of drugs and other bioactive molecules. Hoboken: John Wiley & Sons; 2015. p. 397–409.

  9. 9.

    Rubio-Perez C, et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell. 2015;27(3):382–96.

  10. 10.

    Zhang Y, et al. Pathway of PPAR-gamma coactivators in thermogenesis: a pivotal traditional Chinese medicine-associated target for individualized treatment of rheumatoid arthritis. Oncotarget. 2016;7(13):15885–900.

  11. 11.

    Ehrman TM, Barlow† DJ, Hylands‡ PJ. Phytochemical informatics of Traditional Chinese medicine and therapeutic relevance. J Chem Inf Model. 2007;47(6):2316–34.

  12. 12.

    Liu C, et al. Uncovering pharmacological mechanisms of Wu-tou decoction acting on rheumatoid arthritis through systems approaches: drug-target prediction, network analysis and experimental validation. Scientific Rep. 2015;5:9463.

  13. 13.

    Gao B, et al. Platelet P2Y12 receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng. Br J Pharmacol. 2014;171(1):214.

  14. 14.

    Ji W, et al. Water-compatible molecularly imprinted polymers for selective solid phase extraction of dencichine from the aqueous extract of Panax notoginseng. J Chromatogr B. 2016;1008:225.

  15. 15.

    Esparza E, et al. Bioactive maca (Lepidium meyenii) alkamides are a result of traditional Andean postharvest drying practices. Phytochemistry. 2015;116:138–48.

  16. 16.

    Li Z, et al. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Altern Med eCAM. 2014;2014(33):289264.

  17. 17.

    Liu H-K. Artemisinin, GABA signaling and cell reprogramming: when an old drug meets modern medicine. Sci Bull. 2017;62(6):386–7.

  18. 18.

    Boonen J, et al. Alkamid database: chemistry, occurrence and functionality of plant N-alkylamides. J Ethnopharmacol. 2012;142(3):563–90.

  19. 19.

    Umashankar V, Nandhitha S, Kalabharath P. InPACdb—Indian plant anticancer compounds database. Bioinformation. 2009;4(2):71–4.

  20. 20.

    Kim S-K, et al. TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine. BMC Complement Altern Med. 2015;15(1):218.

  21. 21.

    Fang X, et al. CHMIS-C: a comprehensive herbal medicine information system for cancer. J Med Chem. 2005;48(5):1481–8.

  22. 22.

    Chen L, et al. Identification of compound–protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds. Mol Genet Genomics. 2016;291(6):2065–79.

  23. 23.

    Loub WD, et al. NAPRALERT: computer handling of natural product research data. J Chem Inf Comput Sci. 1985;25(2):99–103.

  24. 24.

    Ihlenfeldt WD, et al. Enhanced CACTVS browser of the open NCI database. J Chem Inf Comput Sci. 2002;42(1):46.

  25. 25.

    Chen CY-C. TCM Database@ Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS ONE. 2011;6(1):e15939.

  26. 26.

    Xue R, et al. TCMID: Traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res. 2013;41(Database issue):D1089.

  27. 27.

    Ru J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13.

  28. 28.

    Luo M, Reid T-E, Simon Wang X. Discovery of natural product-derived 5-HT1A receptor binders by cheminfomatics modeling of known binders, high throughput screening and experimental validation. Comb Chem High Throughput Screen. 2015;18(7):685–92.

  29. 29.

    Yi Y-D, Chang I-M. An overview of traditional Chinese herbal formulae and a proposal of a new code system for expressing the formula titles. Evid Based Complement Altern Med. 2004;1(2):125–32.

  30. 30.

    Irwin JJ, et al. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012;52(7):1757–68.

  31. 31.

    Kerns EH, Li D. Drug-like properties: concepts, structure design and methods. Oxford: Elsevier LTD; 2008. p. 125–6.

  32. 32.

    Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1. Adv Drug Deliv Rev. 2001;46(1–3):3–26.

  33. 33.

    Veber DF, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.

  34. 34.

    Eldehna WM, et al. Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties. Molecules. 2016;21(6):762.

  35. 35.

    Van De Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nature reviews. Drug Discov. 2003;2(3):192.

  36. 36.

    Dhiman V, et al. Characterization of stress degradation products of amodiaquine dihydrochloride by liquid chromatography with high-resolution mass spectrometry and prediction of their properties by using ADMET predictor. J Sep Sci. 2017;40(23):4530–40.

  37. 37.

    Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol. 2005;1(1):159–68.

  38. 38.

    Morris GM, Limwilby M. Molecular docking. New York: Humana Press; 2008. p. 365–82.

  39. 39.

    Sun H. Pharmacophore-based virtual screening. Curr Med Chem. 2008;15(10):1018–24.

  40. 40.

    Najmanovich RJ, et al. Analysis of binding site similarity, small-molecule similarity and experimental binding profiles in the human cytosolic sulfotransferase family. Bioinformatics. 2007;23(2):e104.

  41. 41.

    Ewing TJA, et al. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001;15(5):411–28.

  42. 42.

    Yang H, et al. X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore. Chem Commun. 2017;53(18):2772–5.

  43. 43.

    Chen YC, et al. Prediction of protein pairs sharing common active ligands using protein sequence, structure, and ligand similarity. J Chem Inf Model. 2016;56(9):1734–45.

  44. 44.

    Cosconati S, et al. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov. 2010;5(6):597–607.

  45. 45.

    Allen WJ, et al. DOCK 6: impact of new features and current docking performance. J Comput Chem. 2015;36(15):1132–56.

  46. 46.

    Hart TN, Ness SR, Read RJ. Critical evaluation of the research docking program for the CASP2 challenge. Proteins. 1997;29(Suppl 1):205–9.

  47. 47.

    Sullivan DC, Martin EJ. Exploiting structure-activity relationships in docking. J Chem Inf Model. 2008;48(4):817–30.

  48. 48.

    Zsoldos Z, et al. eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model. 2007;26(1):198–212.

  49. 49.

    Rarey M, et al. A fast flexible docking method using an incremental construction algorithm. J Mol Biol. 1996;261(3):470–89.

  50. 50.

    Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.

  51. 51.

    Jones G, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–48.

  52. 52.

    Hsin KY, et al. systemsDock: a web server for network pharmacology-based prediction and analysis. Nucleic Acids Res. 2016;44(W1):W507–13.

  53. 53.

    Pierce BG, et al. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics. 2014;30(12):1771–3.

  54. 54.

    Arockia Babu M, et al. Development of 3D-QSAR models for 5-lipoxygenase antagonists: chalcones. Bioorg Med Chem. 2002;10(12):4035–41.

  55. 55.

    Liu GY, et al. 3D-QSAR studies of insecticidal anthranilic diamides as ryanodine receptor activators using CoMFA, CoMSIA and DISCOtech. Chemosphere. 2010;78(3):300–6.

  56. 56.

    Vora J, et al. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV. J Biomol Struct Dyn. 2018. https://doi.org/10.1080/07391102.2017.1420489.

  57. 57.

    Patel Y, et al. A comparison of the pharmacophore identification programs: catalyst, DISCO and GASP. J Comput Aided Mol Des. 2002;16(8–9):653–81.

  58. 58.

    Irwin JJ, et al. Predicted biological activity of purchasable chemical space. J Chem Inf Model. 2017. https://doi.org/10.1021/acs.jcim.7b00316.

  59. 59.

    Engels MF, et al. CerBeruS: a system supporting the sequential screening process. J Chem Inf Comput Sci. 2000;40(2):241–5.

  60. 60.

    Lemmen C, Lengauer T, Klebe G. FLEXS: a method for fast flexible ligand superposition. J Med Chem. 1998;41(23):4502–20.

  61. 61.

    Tervo AJ, et al. BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications. J Med Chem. 2005;48(12):4076–86.

  62. 62.

    Yan X, et al. Enhancing molecular shape comparison by weighted Gaussian functions. J Chem Inf Model. 2013;53(8):1967–78.

  63. 63.

    Wermuth CG. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. Methods Princ Med Chem. 2006;32:3.

  64. 64.

    Zuo Z, MacMillan DW. Decarboxylative arylation of α-amino acids via photoredox catalysis: a one-step conversion of biomass to drug pharmacophore. J Am Chem Soc. 2014;136(14):5257–60.

  65. 65.

    Cereto-Massagué A, et al. Molecular fingerprint similarity search in virtual screening. Methods. 2015;71:58–63.

  66. 66.

    Ferreira LG, et al. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384–421.

  67. 67.

    Consortium, U. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017;45(D1):D158–69.

  68. 68.

    Liu T, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007;35(Database issue):D198–201.

  69. 69.

    Chatr-aryamontri A, et al. The BioGRID interaction database: 2017 update. Nucleic Acids Res. 2017;45(D1):D369–79.

  70. 70.

    Dennis G, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(9):R60.

  71. 71.

    Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(suppl_1):D668–72.

  72. 72.

    Mostafavi S, et al. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 2008;9(1):S4.

  73. 73.

    Keshava Prasad TS, et al. Human protein reference database-2009 update. Nucleic Acids Res. 2009;37(Database issue):D767–72.

  74. 74.

    Orchard S, et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42(D1):D358–63.

  75. 75.

    Kanehisa M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61.

  76. 76.

    Deng L, et al. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway. Oncogene. 2017;36(28):3976–85.

  77. 77.

    Licata L, et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 2012;40(1):D857–61.

  78. 78.

    Wang X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017. https://doi.org/10.1093/nar/gkx374.

  79. 79.

    Gao Z, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinform. 2008;9:104.

  80. 80.

    Goodsell DS. The protein data bank, in atomic evidence. Berlin: Springer; 2016. p. 1–4.

  81. 81.

    Croft D, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2014;42(Database issue):D472.

  82. 82.

    Kuhn M, et al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2007;36(suppl_1):D684–8.

  83. 83.

    Szklarczyk D, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014;43(D1):D447–52.

  84. 84.

    Zhu F, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2011;40(D1):D1128–36.

  85. 85.

    Li S. Mapping ancient remedies: applying a network approach to traditional Chinese medicine. Science. 2015;350(6262):S72–4.

  86. 86.

    Krämer A, et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2013;30(4):523–30.

  87. 87.

    Du J, et al. KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway analysis using a path analysis model. Mol BioSyst. 2014;10(9):2441–7.

  88. 88.

    Ekins S, et al. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica. 2006;36(10–11):877–901.

  89. 89.

    Kurata H, et al. Extended CADLIVE: a novel graphical notation for design of biochemical network maps and computational pathway analysis. Nucleic Acids Res. 2007;35(20):e134–e134.

  90. 90.

    Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.

  91. 91.

    Fitts B, et al. dot-app: a Graphviz-Cytoscape conversion plug-in. F1000Research. 2016;5:2543.

  92. 92.

    De Nooy W, Mrvar A, Batagelj V. Exploratory social network analysis with Pajek, vol. 27. Cambridge: Cambridge University Press; 2011.

  93. 93.

    Junker BH, Klukas C, Schreiber F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinform. 2006;7(1):109.

  94. 94.

    Hu Z, et al. VisANT: data-integrating visual framework for biological networks and modules. Nucleic Acids Res. 2005;33(suppl_2):W352–7.

  95. 95.

    Schwarz R, et al. Integrated network reconstruction, visualization and analysis using YANAsquare. BMC Bioinform. 2007;8(1):313.

  96. 96.

    Wan W, et al. Metabolomics reveals that vine tea (Ampelopsis grossedentata) prevents high-fat-diet-induced metabolism disorder by improving glucose homeostasis in rats. PLoS ONE. 2017;12(8):e0182830.

Download references

Authors’ contributions

PGX and HBL designed the methodology. FY performed the experimental computing and data analysis, prepared the figures and wrote the paper. LL, LJX, YMD and HM collected the relevant information. All authors read and approved the final manuscript.

Acknowledgements

We very grateful to Pr. Jun Xu (Research Centerfor Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou) for his valuable suggestions.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable.

Funding

This study was supported by the Beijing Technology and Business University Youth Scholars Fund: PXM2018_014213_000033; and the Key Laboratory of Cosmetic, China National Light Industry, Beijing Technology and Business University Innovation Fund ID: KLC-2017-YB3.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Correspondence to Fan Yi or Hai-bo Liu.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yi, F., Li, L., Xu, L. et al. In silico approach in reveal traditional medicine plants pharmacological material basis. Chin Med 13, 33 (2018) doi:10.1186/s13020-018-0190-0

Download citation

Keywords

  • Traditional medicinal plants
  • Virtual screening
  • Network pharmacology
  • Medicinal plants information analytics
  • Pharmacological basis